TRexBio Prices IPO at $14, Raising $116.7M on Nasdaq

TRex Bio, Inc. announced on 8 October 2026 that it priced its initial public offering of 8,333,334 shares of common stock at $14.00 per share, with all shares offered by the company. Gross proceeds before underwriting discounts, commissions and other offering expenses are expected to be approximately $116.7 million. The South San Francisco-based clinical-stage biotechnology company said its stock is expected to begin trading on the Nasdaq Global Select Market on 9 October 2026 under the ticker symbol TRXB, with the offering expected to close on 13 October 2026, subject to customary closing conditions.

Context — why this biotech IPO matters now

TRexBio is a clinical-stage biotechnology company that describes its focus as tissue Treg biology, the discovery and development of immunoregulatory medicines designed to restore immune balance and promote tissue repair for patients with autoimmune and inflammatory diseases. The company said its Deep Biology Platform decodes Treg functionality in human tissue, mapping drivers of immune dysregulation and uncovering novel targets that inform drug discovery and translational work.

That platform framing is central to how the deal will be read. The company said the platform has generated multiple therapeutic development candidates across its wholly owned pipeline and through collaborations with pharmaceutical partners. TRexBio did not name those partners or disclose how many candidates sit in each bucket.

The report gives no prior valuation, no earlier funding round, no revenue figure and no cash balance, so the pricing cannot be benchmarked against the company's own history. What the report does establish is structure: every share in the deal is primary, meaning the company receives the proceeds rather than selling shareholders.

The trigger for the offering is procedural rather than operational. The company said its registration statement, File No. 333-299018, became effective on 8 October 2026, the same day pricing was announced. A pricing announcement landing on the effective date, with trading two days later, is the standard sequence for a US listing.

Macro conditions for the sector are not described in the report, and no index, rate or peer level is given. Readers comparing this deal to broader biotech issuance will need data the company did not provide.

Data — what the numbers show

The headline figures are straightforward. Shares priced: 8,333,334. Offer price: $14.00. Gross proceeds before discounts, commissions and expenses: approximately $116.7 million. All shares are offered by TRexBio, with none marked as secondary.

Multiplying the share count by the offer price gives roughly $116.7 million, which matches the company's stated gross figure. That consistency confirms the deal size is calculated on the base offering alone, not on the underwriters' option.

The greenshoe is the second lever. TRexBio said it granted the underwriters a 30-day option to purchase up to an additional 1,250,000 shares at the initial public offering price, less underwriting discounts and commissions. If exercised in full, that adds 15 percent to the base share count, taking the total to 9,583,334 shares and lifting gross proceeds to approximately $134.2 million at the same $14.00 price.

Item	Base deal	With full option
Shares	8,333,334	9,583,334
Gross proceeds at $14.00	~$116.7M	~$134.2M

The company did not disclose net proceeds, underwriting discounts and commissions as a percentage, total offering expenses, post-offering share count, market capitalisation, valuation, use of proceeds, or any lock-up terms. Those omissions matter because net proceeds, not gross, determine the cash the company can deploy.

On the syndicate, J.P. Morgan, Evercore ISI, Cantor and Stifel are acting as lead book-running managers. Wedbush PacGrow is acting as book-running manager. The report names no other banks and gives no allocation breakdown.

Analysis — what it means for markets and tickers

The single ticker directly exposed is TRXB, which begins trading on the Nasdaq Global Select Market on 9 October 2026. The deal also touches the listed bookrunners, though the report gives no fee figures that would let an investor size the revenue contribution to J.P. Morgan, Evercore, Cantor, Stifel or Wedbush PacGrow.

The second-order read is sector-level. A completed clinical-stage biotech pricing at $14.00 with roughly $116.7 million gross is a data point for IPO-window sentiment in healthcare, a sector where issuance is sensitive to risk appetite. The report provides no peer pricing, no sector index level and no comparable deal, so this deal cannot be positioned against the biotech issuance calendar on the company's own numbers.

The limitation worth flagging is the gap between gross and net. Gross proceeds of approximately $116.7 million are stated before underwriting discounts and commissions and other offering expenses, and the company disclosed neither figure. Any estimate of the cash TRexBio actually receives would require assumptions the report does not support.

A second counter-argument is clinical, not financial. TRexBio describes itself as clinical-stage, which means its value rests on pipeline readouts rather than commercial revenue. The report gives no trial data, no phase designations and no timelines.

On positioning, the mechanics are visible even without flow data. The 30-day option gives the bookrunners a mechanism to support aftermarket demand, and the 13 October closing date means settlement sits after the first two trading sessions. The company did not disclose lock-up arrangements, so the supply picture beyond the greenshoe is unknown.

Outlook — what to watch next

Three dates are fixed by the report. TRXB is expected to begin trading on the Nasdaq Global Select Market on 9 October 2026. The offering is expected to close on 13 October 2026, subject to customary closing conditions. The underwriters' option runs for 30 days from the deal, and whether it is exercised will surface in subsequent filings.

A fourth marker is procedural. The company said the offering is being made only by means of a prospectus, with copies available from J.P. Morgan Securities LLC and Evercore Group L.L.C. The final prospectus, when available, carries the risk factors the report references but does not reproduce.

No price levels, moving averages or valuation thresholds appear in the report, so there is no technical reference point to set against the $14.00 offer price. The only level the company names is the offer price itself, and the only condition it names is satisfaction of customary closing conditions. Until trading begins, the deal is priced but not distributed.

Frequently Asked Questions

What does the TRexBio IPO mean for retail investors?

Retail investors cannot act before 9 October 2026, when TRXB is expected to begin trading on the Nasdaq Global Select Market. Shares were allocated at $14.00 through the underwriting syndicate, not at a public price. Anyone buying after the debut pays the market price, which the company has not forecast. The report gives no valuation, no net proceeds and no lock-up terms, so post-listing supply is unclear.

What happens next for TRexBio after pricing?

The offering is expected to close on 13 October 2026, subject to customary closing conditions. Between pricing and closing, the underwriters hold a 30-day option on up to 1,250,000 additional shares at $14.00, less discounts and commissions. Exercise of that option would raise total gross proceeds to roughly $134.2 million. The company said the offering is made only by prospectus, and the final prospectus will carry the risk factors.

Why did TRexBio raise roughly $116.7 million?

The report does not state a use of proceeds. What it does confirm is that all 8,333,334 shares are offered by TRexBio, so the company receives the gross proceeds rather than existing shareholders selling into the deal. The registration statement became effective on 8 October 2026, the same day pricing was announced. Net proceeds remain undisclosed because discounts, commissions and offering expenses were not itemised.

Bottom Line

TRexBio priced 8,333,334 shares at $14.00 for about $116.7 million gross, with TRXB set to trade on Nasdaq from 9 October 2026.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.